Two-week vs. three-week chemo for newly diagnosed acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial compares two schedules of a chemotherapy combination (VA-CAG) to see which one works better for patients newly diagnosed with acute myeloid leukemia (AML). The goal is to find the best way to achieve remission with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acute myeloid leukemia (AML).
- You are between 18 and 75 years old.
- Your weight is between 30 and 100 kg (about 66 to 220 pounds).
- You are generally able to care for yourself (performance status score of 3 or less).
- Your heart, liver, and kidneys are working well enough, with no severe organ problems.
- You do not have a severe infection, and you have not had prior treatment for AML.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different strengths of a chemotherapy regimen that includes venetoclax (a targeted pill) for people with newly diagnosed acute myeloid leukemia (AML). The goal is to find which dose works as well or better with fewer side effects, and it may offer a more personalized treatment option for those who can tolerate intensive therapy.
This study tests a combination of three drugs—aclarubicin, azacitidine, and venetoclax—for people with acute myeloid leukemia (AML) who cannot have intensive chemotherapy, or whose leukemia has returned after treatment. The goal is to see if this combination helps control the leukemia with manageable side effects.
This trial tests a combination of three drugs (venetoclax, homoharringtonine, and azacitidine) plus a growth factor to treat newly diagnosed AML in people who aren't strong enough for standard chemo. The goal is to see if this combo can help control the leukemia with fewer side effects.
This trial tests three different chemotherapy regimens for adults 15–65 years old with newly diagnosed acute myeloid leukemia (AML)—a serious blood cancer. The goal is to see which treatment approach works best for patients with intermediate or high-risk disease who are fit enough for intensive chemotherapy.
This trial tests a combination of three drugs—daunorubicin, cytarabine, and venetoclax—for people with newly diagnosed AML who are strong enough to receive intensive chemotherapy. The goal is to see if adding venetoclax helps improve treatment outcomes.
This trial tests a combination of three chemotherapy drugs (venetoclax, azacitidine, and cytarabine) for people newly diagnosed with acute myeloid leukemia who have never received AML treatment before. The goal is to see if this combination can help patients go into remission and live longer.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.